Lilly Makes Big Biologics Play For Alzheimer’s
This article was originally published in The Pink Sheet Daily
Executive Summary
But study published in Lancet raises questions about efficacy of anti-amyloid therapy.
You may also be interested in...
FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools
Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease
FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools
Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.